Explanipedia

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study Open

Xue Bai, Shaheen Ahmed, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina , et al. · 2024

The authors added detailed treatment data which may be valuable information for readers to their study "Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive sur…

Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study Open

Xue Bai, Aleigha Lawless, Juliane A. Czapla, Stefanie Gerstberger, Benjamin C. Park , et al. · 2024

Patient Perspectives on Selecting an Academic Aesthetic Surgeon Open

Shirley Chen, Benjamin C. Park, Alan T. Makhoul, Galen Perdikis, Catherine M. Hammack‐Aviran , et al. · 2023

Background Growth of the aesthetic surgery marketplace has increased patient choice in provider selection. This study aimed to characterize how patients choose an aesthetic surgeon, identify knowledge gaps in this decision-making process, …

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study Open

Xue Bai, Shaheen Ahmed, Charlotte Grieco, Paolo D. d’Arienzo, Florentia Mina , et al. · 2023

PC21. Gender-affirming Surgery is Associated with Improved Patient Reported Outcomes Open

Ya‐Ching Hung, Benjamin C. Park, Patrick E. Assi, Galen Perdikis, Brian C. Drolet , et al. · 2023

PURPOSE: To assess patient reported outcomes of gender-affirming care (GAC) using the Vanderbilt Mini Patient Reported Outcome Measures—Gender (VMP-G), a newly validated psychometric instrument. METHODS: VMP-G assesses four scales: quality…

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations Open

Benjamin C. Park, S. Narayanan, Alexander Gavralidis, Fei Ye, Run Fan , et al. · 2023

Immune-related adverse events (irAEs) are side effects of immune checkpoint inhibitor therapy (ICI). While common irAEs have been well characterized, there are more limited data on rare immune related adverse events (RirAEs) due to low inc…

Recurrence of Hypophysitis After Immune Checkpoint Inhibitor Rechallenge Open

Benjamin C. Park, Seungyeon Jung, J. J. Wright, Douglas B. Johnson · 2022

Immune checkpoint inhibitor (ICI)-induced hypophysitis is an immune-mediated pituitary inflammation that tends to cause long-term pituitary deficiency. Management of ICI-induced hypophysitis includes corticosteroids for acute inflammation …

Immune checkpoint inhibitors and their impact on liver enzymes and attenuation Open

Benjamin C. Park, Aaron Lee, Fei Ye, Isik Turker, Douglas B. Johnson · 2022

75. Development of a Short-form Patient-Reported Outcomes Measure for Gender-Affirming Surgery Open

Benjamin C. Park, Alan T. Makhoul, Kent K. Higdon, Shalyn Vanderbloemen, Julian Winocour , et al. · 2022

Purpose: A critical barrier to measuring outcomes in gender-affirming surgery (GAS) is the lack of a short-form patient-reported outcomes measure (PROM). Although a robust PROM may be necessary for settings that require the highest level o…

P103. PHASE I STUDY PROTOCOL TO DEVELOP A SHORT-FORM PATIENT-REPORTED OUTCOMES MEASURE FOR GENDER-AFFIRMING SURGERY Open

Benjamin C. Park, Alan T. Makhoul, Kent Higdon, Shalyn Vanderbloemen, Julian Winocour , et al. · 2022

PURPOSE: A critical barrier to measuring outcomes in gender-affirming surgery (GAS) is the lack of a short-form patient-reported outcomes measure (PROM). This protocol characterizes the development of a novel GAS PROM, the Vanderbilt Mini …

Benjamin C. Park YOU? Author Swipe